New reports to be issued following a Senate investigation and results from a clinical trial appear to further solidify the dangers associated with Avandia (rosiglitazone). As cited by The New York Times, the reports conclude that if Avandia patients switched to a similar diabetes drug, Actos, approximately 500 heart attacks and 300 cases of heart… Continue Reading